Acoramidis 365 mg tablets contain the active ingredient Acoramidis, a selective transthyretin (TTR) stabilizer used for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a progressive condition caused by the accumulation of misfolded transthyretin protein in the heart, leading to thickening and stiffening of the heart muscle and ultimately heart failure.

Acoramidis works by stabilizing the transthyretin protein in its normal tetrameric structure, preventing it from breaking into unstable monomers that form amyloid fibrils. By preventing this process, the medicine helps slow disease progression and reduce cardiovascular complications associated with ATTR-CM.

Acoramidis is indicated for the treatment of:

Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Cardiomyopathy caused by wild-type transthyretin amyloidosis.

Cardiomyopathy caused by hereditary transthyretin amyloidosis.

This therapy helps slow disease progression and improves cardiovascular outcomes.

Acoramidis acts as a selective stabilizer of transthyretin (TTR). It binds to the thyroxine-binding sites of the TTR protein and prevents dissociation of the tetramer into monomers, which is the critical step that leads to amyloid formation.

By stabilizing TTR, Acoramidis:

Prevents formation of amyloid fibrils.

Reduces deposition of amyloid in heart tissue.

Slows progression of ATTR-CM.

Improves cardiovascular outcomes and reduces hospitalization risk.

Clinical trials have demonstrated that treatment with Acoramidis significantly reduces cardiovascular mortality and heart-failure-related hospitalizations in patients with ATTR-CM.

Acoramidis tablets should be taken orally as prescribed by a healthcare professional.

The typical recommended dose in clinical use corresponds to 712 mg twice daily, which equals two tablets per dose depending on tablet strength.

Tablets may be taken with or without food.

Swallow the tablets whole with water and do not crush or chew them.

The most commonly reported side effects include:

Diarrhoea

Upper abdominal pain

Gastrointestinal discomfort

Most side effects are generally mild and resolve without discontinuation of therapy.

Patients should inform their healthcare provider about all medications they are taking, including prescription drugs, over-the-counter medicines, supplements, and herbal products.

Acoramidis may interact with:

Strong CYP3A inducers

UGT enzyme inducers

Medicines metabolized by CYP2C9

These interactions may affect the effectiveness of the treatment or increase the risk of side effects.

Store at 20°C–25°C (68°F–77°F).

Keep the tablets in their original packaging to protect from moisture.

Keep out of reach of children.

Early diagnosis of transthyretin amyloid cardiomyopathy is important for effective treatment.

Regular cardiovascular monitoring is recommended during therapy.

Patients should follow the prescribed dosing schedule and not stop treatment without consulting their doctor.